Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae

被引:140
作者
Pouliot, JJ [1 ]
Robertson, CA [1 ]
Nash, HA [1 ]
机构
[1] NIMH, Mol Biol Lab, Bethesda, MD 20892 USA
关键词
D O I
10.1046/j.1365-2443.2001.00452.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: The covalent linkage between DNA and the active site tyrosine of topoisomerase I can be stabilized by chemotherapeutic agents, adjacent DNA lesions, or mutational defects in the topoisomerase itself. Following collision with a replication fork, the covalent complex can be converted to a double-strand break. Tdp1, an enzyme that can hydrolyse the bond between topoisomerase I and DNA, is thought to be involved in the repair of these lesions, but little is known about how such repair is accomplished. Results: Reaction kinetics with model substrates reveal that the catalytic efficiency of Saccharomyces cerevisiae Tdp1 is relatively poor when the scissile bond is located in the middle of a duplex, but much better when it is located at the end of a structure. Survival of yeast after induction of a toxic topoisomerase is substantially reduced by inactivation of the TDP1 gene. Comparison of survival of single and double mutants places TDP1 and RAD52 in the same epistasis group but TDP1 and RAD9 in different epistasis groups. In the absence of RAD9, inactivation of MPI has a significant effect on the survival of cells following exposure to camptothecin but is without consequence for the survival of agents that do not target topoisomerase 1. Conclusions: Tdp1 acts as a specific repair enzyme for topoisomerase I lesions. Rather than working at their earliest occurrence, the enzyme acts after covalent complexes have been converted to DSBs. A second repair pathway also exists that functions independently of Tdp1 but requires RAD9 function to efficiently repair topoisomerase I-linked DSBs. The efficiency of these pathways differs for complexes induced with the chemotherapeutic agent camptothecin vs. those accumulated by mutant forms of topoisomerase 1.
引用
收藏
页码:677 / 687
页数:11
相关论文
共 37 条
[11]  
ENG WK, 1988, MOL PHARMACOL, V34, P755
[12]   Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin [J].
Fan, Y ;
Weinstein, JN ;
Kohn, KW ;
Shi, LM ;
Pommier, Y .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) :2216-2226
[13]   COMPLETE DNA-SEQUENCE OF YEAST CHROMOSOME-II [J].
FELDMANN, H ;
AIGLE, M ;
ALJINOVIC, G ;
ANDRE, B ;
BACLET, MC ;
BARTHE, C ;
BAUR, A ;
BECAM, AM ;
BITEAU, N ;
BOLES, E ;
BRANDT, T ;
BRENDEL, M ;
BRUCKNER, M ;
BUSSEREAU, F ;
CHRISTIANSEN, C ;
CONTRERAS, R ;
CROUZET, M ;
CZIEPLUCH, C ;
DEMOLIS, N ;
DELAVEAU, T ;
DOIGNON, F ;
DOMDEY, H ;
DUSTERHUS, S ;
DUBOIS, E ;
DUJON, B ;
ELBAKKOURY, M ;
ENTIAN, KD ;
FEUERMANN, M ;
FIERS, W ;
FOBO, GM ;
FRITZ, C ;
GASSENHUBER, H ;
GLANSDORFF, N ;
GOFFEAU, A ;
GRIVELL, LA ;
DEHAAN, M ;
HEIN, C ;
HERBERT, CJ ;
HOLLENBERG, CP ;
HOLMSTROM, K ;
JACQ, C ;
JACQUET, M ;
JAUNIAUX, JC ;
JONNIAUX, JL ;
KALLESOE, T ;
KIESAU, P ;
KIRCHRATH, L ;
KOTTER, P ;
KOROLL, S ;
LIEBL, S .
EMBO JOURNAL, 1994, 13 (24) :5795-5809
[14]   Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells:: abrogation of S/G2 arrest [J].
Jones, CB ;
Clements, MK ;
Wasi, S ;
Daoud, SS .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (03) :252-258
[15]   Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death [J].
Megonigal, MD ;
Fertala, J ;
Bjornsti, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (19) :12801-12808
[16]   Base excision repair in yeast and mammals [J].
Memisoglu, A ;
Samson, L .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 451 (1-2) :39-51
[17]   DNA TOPOISOMERASE-TARGETING ANTITUMOR DRUGS CAN BE STUDIED IN YEAST [J].
NITISS, J ;
WANG, JC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (20) :7501-7505
[18]   USING YEAST TO STUDY RESISTANCE TO TOPOISOMERASE II-TARGETING DRUGS [J].
NITISS, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 :S6-S13
[19]  
Nitiss JL, 1996, MOL PHARMACOL, V50, P1095
[20]   Camptothecins: a review of their development and schedules of administration [J].
O'Leary, J ;
Muggia, FM .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1500-1508